FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163980212> ?p ?o ?g. }

• W2163980212 endingPage "830" @default.
• W2163980212 startingPage "814" @default.
• W2163980212 abstract "Pediatric AnesthesiaVolume 15, Issue 10 p. 814-830 Intraoperative pediatric blood transfusion therapy: a review of common issues. Part II: transfusion therapy, special considerations, and reduction of allogenic blood transfusions SANDRA L. BARCELONA MD, SANDRA L. BARCELONA MD Departments of AnesthesiologySearch for more papers by this authorALEXIS A. THOMPSON MD, ALEXIS A. THOMPSON MD Pediatrics, The Feinberg School of Medicine at Northwestern University, Chicago, IL, USA and Departments of Hematology-Oncology-Stem Cell Transplantation, Children's Memorial Hospital, Chicago, IL, USASearch for more papers by this authorCHARLES J. COTÉ MD, CHARLES J. COTÉ MD Departments of Anesthesiology Pediatrics, The Feinberg School of Medicine at Northwestern University, Chicago, IL, USA and Departments of Pediatric AnesthesiologySearch for more papers by this author SANDRA L. BARCELONA MD, SANDRA L. BARCELONA MD Departments of AnesthesiologySearch for more papers by this authorALEXIS A. THOMPSON MD, ALEXIS A. THOMPSON MD Pediatrics, The Feinberg School of Medicine at Northwestern University, Chicago, IL, USA and Departments of Hematology-Oncology-Stem Cell Transplantation, Children's Memorial Hospital, Chicago, IL, USASearch for more papers by this authorCHARLES J. COTÉ MD, CHARLES J. COTÉ MD Departments of Anesthesiology Pediatrics, The Feinberg School of Medicine at Northwestern University, Chicago, IL, USA and Departments of Pediatric AnesthesiologySearch for more papers by this author First published: 13 September 2005 https://doi.org/10.1111/j.1460-9592.2004.01549.xCitations: 65 Sandra L. Barcelona, Department of Pediatric Anesthesiology (Box 19), Children's Memorial Hospital, 2300 Children's Plaza, Chicago, IL 60614, USA (email: [email protected]). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Coté CJ, Liu LM, Szyfelbein SK et al. Changes in serial platelet counts following massive blood transfusion in pediatric patients. Anesthesiology 1985; 62: 197–201. 2 Coté CJ. Blood, colloid, and crystalloid therapy. Anesth Clin North Am 1991; 9: 865–884. 3 Barcelona SL, Coté CJ. Pediatric resuscitation in the operating room. Anesthesiol Clin North Am 2001; 19: 339–365. 4 Miller RD. Complications of massive blood transfusions. Anesthesiology 1973; 39: 82–93. 5 Butenas S, Brummel KE, Bouchard BA et al. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1: 1158–1160. 6 Schlesinger KW, Ragni MV. Safety of the new generation recombinant factor concentrates. Expert Opin Drug Saf 2002; 1: 213–223. 7 Shapiro AD. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost 2000; 26: 413–419. 8 Seremetis S. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors. Blood Coagul Fibrinolysis 2003; 14 Suppl 1: S29–S30. 9 Dejgaard A. Update on Novo Nordisk's clinical trial programme on NovoSeven. Blood Coagul Fibrinolysis 2003; 14 Suppl. 1: S39–S41. 10 Girard TJ, Nicholson NS. The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation. Curr Opin Pharmacol 2001; 1: 159–163. 11 Midathada MV, Mehta P, Waner M et al. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol 2004; 121: 124–137. 12 Gerotziafas GT, Chakroun T, Depasse F et al. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004; 91: 977–985. 13 Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003; 361: 161–169. 14 Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003; 24: 607–622. 15 Laurian Y. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa? Pathophysiol Haemost Thromb 2002; 32 Suppl. 1: 37–40. 16 Lynn M, Jeroukhimov I, Klein Y et al. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 2002; 28 Suppl 2: S241–S247. 17 Jurlander B, Thim L, Klausen NK et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001; 27: 373–384. 18 Poon MC. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa? Curr Hematol Rep 2003; 2: 139–147. 19 Kjalke M, Ezban M, Monroe DM et al. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001; 114: 114–120. 20 Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19: 163–176. 21 Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000; 26: 385–391. 22 Abshire TC. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing. Semin Hematol 2004; 41 Suppl. 1: 3–7. 23 Martinowitz U, Kenet G, Lubetski A et al. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002; 49: S15–S20. 24 Al Douri M, Shafi T, Al Khudairi D et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11 Suppl. 1: S121–S127. 25 White B, McHale J, Ravi N et al. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999; 107: 677–678. 26 O'Neill PA, Bluth M, Gloster ES et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002; 52: 400–405. 27 Markiewicz M, Kalicinski P, Kaminski A et al. Acute coagulopathy after reperfusion of the liver graft in children correction with recombinant activated factor VII. Transplant Proc 2003; 35: 2318–2319. 28 Naik VN, Mazer CD, Latter DA et al. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth 2003; 50: 599–602. 29 Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J Clin Anesth 2003; 15: 184–188. 30 Eikelboom JW, Bird R, Blythe D et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003; 14: 713–717. 31 Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb 2002; 32 Suppl. 1: 41–46. 32 Meijer K, Hendriks HG, de Wolf JT et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 2003; 14: 169–174. 33 Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients. Report of three cases and review of the literature. J Neurosurg 2003; 98: 611–616. 34 Martinowitz U, Kenet G, Segal E et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431–438. 35 Martinowitz U, Holcomb JB, Pusateri AE et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001; 50: 721–729. 36 Surudo T, Wojcicki M, Milkiewicz P et al. Rapid correction of prothrombin time after low-dose recombinant factor VIIA in patients undergoing orthotopic liver transplantation. Transplant Proc 2003; 35: 2323–2325. 37 Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol 2004; 41 Suppl. 1: 20–24. 38 Rajwal S, Richards M, O'Meara M. The use of recalcified citrated whole blood – a pragmatic approach for thromboelastography in children. Paediatr Anaesth 2004; 14: 656–660. 39 Srinivasa V, Gilbertson LI, Bhavani-Shankar K. Thromboelastography: where is it and where is it heading? Int Anesthesiol Clin 2001; 39: 35–49. 40 Whitten CW, Greilich PE. Thromboelastography: past, present, and future. Anesthesiology 2000; 92: 1223–1225. 41 Dunkley SM, Mackie F. Recombinant factor VIIa used to control massive haemorrhage during renal transplantation surgery; vascular graft remained patent. Hematology 2003; 8: 263–264. 42 Tobias JD, Berkenbosch JW, Muruve NA et al. Correction of a coagulopathy using recombinant factor VII before removal of an intra-aortic balloon pump. J Cardiothorac Vasc Anesth 2002; 16: 612–614. 43 Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003; 4: 49–51. 44 Pychynska-Pokorska M, Moll JJ, Krajewski W et al. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 2004; 5: 246–250. 45 Egan JR, Lammi A, Schell DN et al. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 2003; 30: 682–685. 46 Brown JB, Emerick KM, Brown DL et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003; 37: 268–272. 47 Chuansumrit A, Visanuyothin N, Puapunwattana S et al. Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency. J Med Assoc Thai 2002; 85 Suppl. 4: S1059–S1064. 48 Chuansumrit A, Chantarojanasiri T, Isarangkura P et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000; 11 Suppl. 1: S101–S105. 49 Almeida AM, Khair K, Hann I et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477–481. 50 Veldman A, Fischer D, Voigt B et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med 2002; 28: 1635–1637. 51 Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis 2003; 14: 117–120. 52 Sauaia A, Moore FA, Moore EE et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995; 38: 185–193. 53 Pinsky MR. Probing the limits of arterial pulse contour analysis to predict preload responsiveness. Anesth Analg 2003; 96: 1245–1247. 54 Idris A, Melker RJ. High-flow sheaths for pediatric fluid resuscitation: a comparison of flow rates with standard pediatric catheters. Pediatr Emerg Care 1992; 8: 119–122. 55 Goldstein B, Doody D, Briggs S. Emergency intraosseous infusion in severely burned children. Pediatr Emerg Care 1990; 6: 195–197. 56 Tighe SQ, Rudland SV, Kemp PM et al. Paediatric resuscitation in adverse circumstances: a comparison of three routes of systemic access. J R Nav Med Serv 1993; 79: 75–79. 57 Velasco AL, Delgado-Paredes C, Templeton J et al. Intraosseous infusion of fluids in the initial management of hypovolemic shock in young subjects. J Pediatr Surg 1991; 26: 4–8. 58 Wade CE, Grady JJ, Kramer GC. Efficacy of hypertonic saline dextran fluid resuscitation for patients with hypotension from penetrating trauma. J Trauma 2003; 54 Suppl. 5: S144–S148. 59 Wade CE, Grady JJ, Kramer GC et al. Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension. J Trauma 1997; 42 Suppl. 5: S61–S65. 60 Maningas PA, Mattox KL, Pepe PE et al. Hypertonic saline-dextran solutions for the prehospital management of traumatic hypotension. Am J Surg 1989; 157: 528–533. 61 Stump DC, Strauss RG, Henriksen RA et al. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 1985; 25: 349–354. 62 Strauss RG, Stump DC, Henriksen RA et al. Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis. Transfusion 1985; 25: 230–234. 63 Patt A, McCroskey BL, Moore EE. Hypothermia-induced coagulopathies in trauma. Surg Clin North Am 1988; 68: 775–785. 64 Counts RB, Haisch C, Simon TL et al. Hemostasis in massively transfused trauma patients. Ann Surg 1979; 190: 91–99. 65 Murray DJ, Olson J, Strauss R et al. Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology 1988; 69: 839–845. 66 Coté CJ. Changes in prothrombin and partial thromboplastin times during massive blood loss in children undergoing Harrington rod instrumentation. Section on Anesthesiology. American Academy of Pediatrics, 1988. 67 Murray DJ, Pennell BJ, Weinstein SL et al. Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg 1995; 80: 336–342. 68 Cohen A, Manno C. Transfusion practices in infants receiving assisted ventilation. Clin Perinatol 1998; 25: 97–111. 69 Warren LJ, Simmer K, Roxby D et al. DNA polymorphism analysis in transfusion-associated graft-versus-host disease. J Paediatr Child Health 1999; 35: 98–101. 70 Floss AM, Strauss RG, Goeken N et al. Multiple transfusions fail to provoke antibodies against blood cell antigens in human infants. Transfusion 1986; 26: 419–422. 71 Manno CS. What's new in transfusion medicine? Pediatr Clin North Am 1996; 43: 793–808. 72 DePalma L, Yu M, McIntosh CL et al. Changes in lymphocyte subpopulations as a result of cardiopulmonary bypass. The effect of blood transfusion. J Thorac Cardiovasc Surg 1991; 101: 240–244. 73 Colon-Otero G, Gilchrist GS, Holcomb GR et al. Preoperative evaluation of hemostasis in patients with congenital heart disease. Mayo Clin Proc 1987; 62: 379–385. 74 Gill JC, Wilson AD, Endres-Brooks J et al. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986; 67: 758–761. 75 Chambers LA, Cohen DM, Davis JT. Transfusion patterns in pediatric open heart surgery. Transfusion 1996; 36: 150–154. 76 Petaja J, Lundstrom U, Leijala M et al. Bleeding and use of blood products after heart operations in infants. J Thorac Cardiovasc Surg 1995; 109: 524–529. 77 Kern FH, Morana NJ, Sears JJ et al. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 541–546. 78 Miller BE, Mochizuki T, Levy JH et al. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg 1997; 85: 1196–1202. 79 Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. Anesth Analg 1999; 89: 57–64. 80 von Segesser LK, Tozzi P, Mallbiabrrena I et al. Miniaturization in cardiopulmonary bypass. Perfusion 2003; 18: 219–224. 81 Friesen RH, Campbell DN, Clarke DR et al. Modified ultrafiltration attenuates dilutional coagulopathy in pediatric open heart operations. Ann Thorac Surg 1997; 64: 1787–1789. 82 Friesen RH, Tornabene MA, Coleman SP. Blood conservation during pediatric cardiac surgery: ultrafiltration of the extracorporeal circuit volume after cardiopulmonary bypass. Anesth Analg 1993; 77: 702–707. 83 Stein JI, Gombotz H, Rigler B et al. Open heart surgery in children of Jehovah's Witnesses: extreme hemodilution on cardiopulmonary bypass. Pediatr Cardiol 1991; 12: 170–174. 84 Mossad E, Estafanous F. Blood use in cardiac surgery and the limitations of hemodilution. Curr Opin Cardiol 1995; 10: 584–590. 85 Fukumura F, Sese A, Ueno Y et al. Haemostatic profile of small children during and following cardiopulmonary bypass. Jpn J Thorac Cardiovasc Surg 2003; 51: 577–581. 86 Nakamura Y, Masuda M, Toshima Y et al. Comparative study of cell saver and ultrafiltration nontransfusion in cardiac surgery. Ann Thorac Surg 1990; 49: 973–978. 87 Dittrich S, Aktuerk D, Seitz S et al. Effects of ultrafiltration and peritoneal dialysis on proinflammatory cytokines during cardiopulmonary bypass surgery in newborns and infants. Eur J Cardiothorac Surg 2004; 25: 935–940. 88 Ootaki Y, Yamaguchi M, Yoshimura N et al. Efficacy of a criterion-driven transfusion protocol in patients having pediatric cardiac surgery. J Thorac Cardiovasc Surg 2004; 127: 953–958. 89 Mossinger H, Dietrich W, Braun SL et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003; 75: 430–437. 90 Pouard P. Review of efficacy parameters. Ann Thorac Surg 1998; 65 Suppl. 6: S40–S43. 91 Huang H, Ding W, Su Z et al. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993; 106: 11–18. 92 Coniff RF. The Bayer 022 compassionate-use pediatric study. Ann Thorac Surg 1998; 65 Suppl. 6: S31–S33. 93 Boldt J, Knothe C, Zickmann B et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg 1993; 105: 705–711. 94 Ranucci M, Corno A, Pavesi M et al. Renal effects of low dose aprotinin in pediatric cardiac surgery. Minerva Anestesiol 1994; 60: 361–366. 95 Dobkowski WB, Murkin JM. A risk-benefit assessment of aprotinin in cardiac surgical procedures. Drug Saf 1998; 18: 21–41. 96 Cohen DM, Norberto J, Cartabuke R et al. Severe anaphylactic reaction after primary exposure to aprotinin. Ann Thorac Surg 1999; 67: 837–838. 97 Carrel TP, Schwanda M, Vogt PR et al. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998; 66: 153–158. 98 D'Errico CC. Pharmacoeconomics analysis in a pediatric population. Ann Thorac Surg 1998; 65 Suppl. 6: S52–S54. 99 Mossinger H, Dietrich W. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Ann Thorac Surg 1998; 65 Suppl. 6: S45–S50. 100 Dietrich W. Incidence of hypersensitivity reactions. Ann Thorac Surg 1998; 65 Suppl. 6: S60–S64. 101 Dietrich W, Spath P, Ebell A et al. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997; 113: 194–201. 102 Handler SD, Miller L, Richmond KH et al. Post-tonsillectomy hemorrhage: incidence, prevention and management. Laryngoscope 1986; 96: 1243–1247. 103 Crysdale WS, Russel D. Complications of tonsillectomy and adenoidectomy in 9409 children observed overnight. CMAJ 1986; 135: 1139–1142. 104 Wei JL, Beatty CW, Gustafson RO. Evaluation of posttonsillectomy hemorrhage and risk factors. Otolaryngol Head Neck Surg 2000; 123: 229–235. 105 Postma DS, Folsom F. The case for an outpatient ‘‘approach’’ for all pediatric tonsillectomies and/or adenoidectomies: a 4-year review of 1419 cases at a community hospital. Otolaryngol Head Neck Surg 2002; 127: 101–108. 106 Asaf T, Reuveni H, Yermiahu T et al. The need for routine pre-operative coagulation screening tests (prothrombin time PT/partial thromboplastin time PTT) for healthy children undergoing elective tonsillectomy and/or adenoidectomy. Int J Pediatr Otorhinolaryngol 2001; 61: 217–222. 107 Zwack GC, Derkay CS. The utility of preoperative hemostatic assessment in adenotonsillectomy. Int J Pediatr Otorhinolaryngol 1997; 39: 67–76. 108 Krishna P, Lee D. Post-tonsillectomy bleeding: a meta-analysis. Laryngoscope 2001; 111: 1358–1361. 109 Close HL, Kryzer TC, Nowlin JH et al. Hemostatic assessment of patients before tonsillectomy: a prospective study. Otolaryngol Head Neck Surg 1994; 111: 733–738. 110 Lippi G, Manzato F, Franchini M et al. Establishment of reference values for the PFA-100 platelet function analyzer in pediatrics. Clin Exp Med 2001; 1: 69–70. 111 Fressinaud E, Veyradier A, Truchaud F et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91: 1325–1331. 112 Derkay CS, Werner E, Plotnick E. Management of children with von Willebrand disease undergoing adenotonsillectomy. Am J Otolaryngol 1996; 17: 172–177. 113 Judkins JH, Dray TG, Hubbell RN. Intraoperative ketorolac and posttonsillectomy bleeding. Arch Otolaryngol Head Neck Surg 1996; 122: 937–940. 114 Splinter WM, Rhine EJ, Roberts DW et al. Preoperative ketorolac increases bleeding after tonsillectomy in children. Can J Anaesth 1996; 43: 560–563. 115 Gunter JB, Varughese AM, Harrington JF et al. Recovery and complications after tonsillectomy in children: a comparison of ketorolac and morphine. Anesth Analg 1995; 81: 1136–1141. 116 Gallagher JE, Blauth J, Fornadley JA. Perioperative ketorolac tromethamine and postoperative hemorrhage in cases of tonsillectomy and adenoidectomy. Laryngoscope 1995; 105: 606–609. 117 Rusy LM, Houck CS, Sullivan LJ et al. A double-blind evaluation of ketorolac tromethamine versus acetaminophen in pediatric tonsillectomy: analgesia and bleeding. Anesth Analg 1995; 80: 226–229. 118 Romsing J, Ostergaard D, Walther-Larsen S et al. Analgesic efficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomy. Acta Anaesthesiol Scand 1998; 42: 770–775. 119 Agrawal A, Gerson CR, Seligman I et al. Postoperative hemorrhage after tonsillectomy: use of ketorolac tromethamine. Otolaryngol Head Neck Surg 1999; 120: 335–339. 120 Kovesi T, Royston D. Pharmacological approaches to reducing allogeneic blood exposure. Vox Sang 2003; 84: 2–10. 121 Goobie SM, Soriano SG, Zurakowski D et al. Hemostatic changes in pediatric neurosurgical patients as evaluated by thrombelastograph. Anesth Analg 2001; 93: 887–892. 122 Curreri PW, Hicks JE, Aronoff RJ et al. Inhibition of active sodium transport in erythrocytes from burned patients. Surg Gynecol Obstet 1974; 139: 538–540. 123 Simon TL, Curreri PW, Harker LA. Kinetic characterization of hemostasis in thermal injury. J Lab Clin Med 1977; 89: 702–711. 124 Cullen JJ, Murray DJ, Kealey GP. Changes in coagulation factors in patients with burns during acute blood loss. J Burn Care Rehabil 1989; 10: 517–522. 125 Sheridan RL, Szyfelbein SK. Trends in blood conservation in burn care. Burns 2001; 27: 272–276. 126 Ikeda S, Schweiss JF. Maximum infusion rates and CVP accuracy during high-flow delivery through multilumen catheters. Crit Care Med 1985; 13: 586–588. 127 Nissenson AR, Strobos J. Iron deficiency in patients with renal failure. Kidney Int Suppl 1999; 69: S18–S21. 128 Montini G, Zacchello G, Baraldi E et al. Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr 1990; 117: 556–560. 129 Chavers BM, Sullivan EK, Tejani A et al. Pre-transplant blood transfusion and renal allograft outcome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 1997; 1: 22–28. 130 Butt ML, Shafi T, Farooqi I et al. Effect of dialysis on bleeding time in chronic renal failure. J Pak Med Assoc 1998; 48: 242–244. 131 Remuzzi G, Livio M, Marchiaro G et al. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 1978; 22: 347–353. 132 Mannucci PM, Remuzzi G, Pusineri F et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8–12. 133 Bontempo FA, Lewis JH, Van Thiel DH et al. The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation 1985; 39: 532–536. 134 Carlier M, Van Obbergh LJ, Veyckemans F et al. Hemostasis in children undergoing liver transplantation. Semin Thromb Hemost 1993; 19: 218–222. 135 Eckhoff DE, D'Alessandro AM, Knechtle SJ et al. 100 consecutive liver transplants in infants and children: an 8-year experience. J Pediatr Surg 1994; 29: 1135–1139. 136 Kalayoglu M, D'Alessandro AM, Sollinger HW et al. Experience with reduced-size liver transplantation. Surg Gynecol Obstet 1990; 171: 139–147. 137 Basford TJ, Poenaru D, Silva M. Comparison of delayed complications of central venous catheters placed surgically or radiologically in pediatric oncology patients. J Pediatr Surg 2003; 38: 788–792. 138 Randolph AG, Cook DJ, Gonzales CA et al. Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature. Crit Care Med 1996; 24: 2053–2058. 139 Goodnough LT, Brecher ME, Kanter MH et al. Transfusion medicine. First of two parts–blood transfusion. N Engl J Med 1999; 340: 438–447. 140 Goodnough LT, Brecher ME, Kanter MH et al. Transfusion medicine. Second of two parts – blood conservation. N Engl J Med 1999; 340: 525–533. 141 Mayer MN, de Montalembert M, Audat F et al. Autologous blood donation for elective surgery in children weighing 8–25 kg. Vox Sang 1996; 70: 224–228. 142 Copley LA, Richards BS, Safavi FZ et al. Hemodilution as a method to reduce transfusion requirements in adolescent spine fusion surgery. Spine 1999; 24: 219–222. 143 Goodnough LT. Erythropoietin therapy versus red cell transfusion. Curr Opin Hematol 2001; 8: 405–410. 144 Rosencher N, Ozier Y. [Peri-operative use of EPO]. Transfus Clin Biol 2003; 10: 159–164. 145 Tamir L, Fradin Z, Fridlander M et al. Recombinant human erythropoietin reduces allogeneic blood transfusion requirements in patients undergoing major orthopedic surgery. Haematologia (Budap) 2000; 30: 193–201. 146 Feagan BG, Wong CJ, Kirkley A et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133: 845–854. 147 Horiba K, Itou Y, Terada H et al. Experience of predeposit autologous blood transfusion and medication of recombinant human erythropoietin in pediatric open heart surgery. Kyobu Geka 1991; 44: 1146–1150. 148 Ley SJ. Intraoperative and postoperative blood salvage. AACN Clin Issues 1996; 7: 238–248. 149 Napier JA, Bruce M, Chapman J et al. Guidelines for autologous transfusion. II. Perioperative haemodilution and cell salvage. British Committee for Standards in Haematology Blood Transfusion Task Force. Autologous Transfusion Working Party. Br J Anaesth 1997; 78: 768–771. 150 Elias D, Lapierre V, Billard V. Perioperative autotransfusion with salvage blood in cancer surgery. Ann Fr Anesth Reanim 2000; 19: 739–744. Citing Literature Volume15, Issue10October 2005Pages 814-830 ReferencesRelatedInformation" @default.
• W2163980212 created "2016-06-24" @default.
• W2163980212 creator A5024453373 @default.
• W2163980212 creator A5038535078 @default.
• W2163980212 creator A5070018581 @default.
• W2163980212 date "2005-09-13" @default.
• W2163980212 modified "2023-10-10" @default.
• W2163980212 title "Intraoperative pediatric blood transfusion therapy: a review of common issues. Part II: transfusion therapy, special considerations, and reduction of allogenic blood transfusions" @default.
• W2163980212 cites W10822334 @default.
• W2163980212 cites W108362734 @default.
• W2163980212 cites W113731524 @default.
• W2163980212 cites W1495536584 @default.
• W2163980212 cites W1867840617 @default.
• W2163980212 cites W190408506 @default.
• W2163980212 cites W1964307571 @default.
• W2163980212 cites W1969243431 @default.
• W2163980212 cites W1973491036 @default.
• W2163980212 cites W1975210832 @default.
• W2163980212 cites W1976923618 @default.
• W2163980212 cites W1978949721 @default.
• W2163980212 cites W1979048031 @default.
• W2163980212 cites W1979792970 @default.
• W2163980212 cites W1980477894 @default.
• W2163980212 cites W1982567501 @default.
• W2163980212 cites W1985942326 @default.
• W2163980212 cites W1986951589 @default.
• W2163980212 cites W1987114459 @default.
• W2163980212 cites W1987753624 @default.
• W2163980212 cites W1988165262 @default.
• W2163980212 cites W1988344879 @default.
• W2163980212 cites W1989663663 @default.
• W2163980212 cites W1990742854 @default.
• W2163980212 cites W1991249049 @default.
• W2163980212 cites W1992106745 @default.
• W2163980212 cites W1993483252 @default.
• W2163980212 cites W1993657377 @default.
• W2163980212 cites W1994378987 @default.
• W2163980212 cites W1995380612 @default.
• W2163980212 cites W1998897601 @default.
• W2163980212 cites W1999740505 @default.
• W2163980212 cites W2001194574 @default.
• W2163980212 cites W2003783373 @default.
• W2163980212 cites W2004768344 @default.
• W2163980212 cites W2005946570 @default.
• W2163980212 cites W2006192038 @default.
• W2163980212 cites W2006374009 @default.
• W2163980212 cites W2006692085 @default.
• W2163980212 cites W2010824815 @default.
• W2163980212 cites W2011330050 @default.
• W2163980212 cites W2011356417 @default.
• W2163980212 cites W2015665816 @default.
• W2163980212 cites W2017301715 @default.
• W2163980212 cites W2018182134 @default.
• W2163980212 cites W2019201121 @default.
• W2163980212 cites W2020674338 @default.
• W2163980212 cites W2021052835 @default.
• W2163980212 cites W2021677594 @default.
• W2163980212 cites W2022974416 @default.
• W2163980212 cites W2027199532 @default.
• W2163980212 cites W2029922917 @default.
• W2163980212 cites W2031772064 @default.
• W2163980212 cites W2032637315 @default.
• W2163980212 cites W2032792086 @default.
• W2163980212 cites W2035505668 @default.
• W2163980212 cites W2035821656 @default.
• W2163980212 cites W2037652834 @default.
• W2163980212 cites W2037699459 @default.
• W2163980212 cites W2037950616 @default.
• W2163980212 cites W2042682482 @default.
• W2163980212 cites W2045794260 @default.
• W2163980212 cites W2046780165 @default.
• W2163980212 cites W2047493899 @default.
• W2163980212 cites W2047769455 @default.
• W2163980212 cites W2047871701 @default.
• W2163980212 cites W2049670083 @default.
• W2163980212 cites W2052500502 @default.
• W2163980212 cites W2054172922 @default.
• W2163980212 cites W2055207386 @default.
• W2163980212 cites W2055781719 @default.
• W2163980212 cites W2056551022 @default.
• W2163980212 cites W2058296078 @default.
• W2163980212 cites W2058411952 @default.
• W2163980212 cites W2059268071 @default.
• W2163980212 cites W2059537328 @default.
• W2163980212 cites W2063038576 @default.
• W2163980212 cites W2063326408 @default.
• W2163980212 cites W2065746572 @default.
• W2163980212 cites W2067143062 @default.
• W2163980212 cites W2067390028 @default.
• W2163980212 cites W2068266143 @default.
• W2163980212 cites W2068472436 @default.
• W2163980212 cites W2072223552 @default.
• W2163980212 cites W2072595162 @default.
• W2163980212 cites W2073316889 @default.
• W2163980212 cites W2074776307 @default.
• W2163980212 cites W2077226930 @default.
• W2163980212 cites W2079925739 @default.
• W2163980212 cites W2080698085 @default.

• next